All Posts

Investigational Pill for Postpartum Depression Shows Promise in Clinical Trial Led by the Feinstein Institutes

Scientists from The Feinstein Institutes for Medical Research have announced the publication of results from a phase 3 clinical trial looking at the safety and efficacy of the oral neuroactive steroid zuranolone (30mg) in the treatment of patients with postpartum depression (PPD). The findings published in the Journal of the American Medical Association (JAMA) Psychiatry showed that after two weeks of daily treatment, women treated…

Maven Expands Its Women’s and Familty Health Offering as Dr. Neel Shah Becomes the Company’s New Chief Medical Officer

Maven, the leading virtual clinic for women’s and family health, today announced that it has hired Dr. Neel Shah, MD, MPP, FACOG, as Chief Medical Officer. A globally recognized expert in designing solutions that improve health care, Dr. Shah brings deep experience as a physician, professor and social entrepreneur to Maven. “Joining Maven presents a unique opportunity for me to build the…

New Report: Fertility at Work (Carrot Fertility & RESOLVE)

Carrot Fertility has released a new report examining the effects of fertility and family forming in the workplace. The report, Fertility at Work, was developed in collaboration with RESOLVE: The National Infertility Association and surveyed over 1,000 respondents about the role of fertility and family forming in workforces, as well as the need for support as employees navigate the complex and emotional…

New Collection of Papers Launches at Gender Equality Forum to Provide Insights into How to Advance Women’s Health and Gender Equality

The World Health Organization (WHO), the United Nations Special Programme HRP and the United Nations University International Institute for Global Health (UNU-IIGH) in partnership with the British Medical Journal (BMJ), have today released a special series of papers on “Women’s Health and Gender Inequalities.” The series celebrates and interrogates collective progress towards making the 1995 Beijing Declaration and Platform for Action on Women a reality…

Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1 Supporting its Potential as the First Monthly Therapy for both the Vasomotor and Vaginal Symptoms of Menopause

Daré Bioscience has announced positive topline results from its Phase 1 clinical trial of DARE-HRT1. DARE-HRT1 is a novel IVR designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy (HT) regimen to treat the vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause. The topline data from the study support DARE-HRT1’s potential to…

AOA Dx Raises a $2.5 Million Seed Round to Develop the First Non-invasive Ovarian Cancer Liquid Biopsy Diagnostic Test 

AOA Dx earlier today announced that they have been accepted to Y Combinator’s 2021 summer cohort and have closed a $2.5 million seed round to develop AKRIVIS GD, a liquid biopsy test that is set to revolutionize the future of ovarian cancer diagnostics.  AOA Dx has been working in close collaboration with world renowned cancer researcher Professor H. Uri Saragovi, Senior Investigator…

Presagen’s Life Whisperer Launches its Third Global IVF Clinic Collaboration to Apply AI to Oocytes

Life Whisperer, fertility arm of AI healthcare company Presagen, will invite clinics to participate in its third global IVF clinic collaboration at the 37th European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting. The AI Open Project aims to apply AI to the assessment of oocytes, or female eggs prior to fertilization or freezing. Oocyte evaluation will be Life Whisperer’s third…